Key Highlights

  • 0.57 is the negative consensus EPS estimate per the screener snapshot for Tvardi Therapeutics, Inc. (NASDAQ:TVRD), which is due to report third quarter 2026 results before the market opens on November 13, 2026.
  • 15.8 million is the USD in cash, cash equivalents and short-term investments at June 30, 2026, down from USD 30.8 million at year-end, with management guiding to a runway into the third quarter of 2027.
  • 6.5 million is the USD net loss for the second quarter of 2026, or USD 0.69 per share, versus Net Income of USD 4.2 million a year earlier that included a USD 12.7 million non-cash gain.
  • 17.87 million is the USD market Capitalization per the screener snapshot, a nano-cap level, while TTI-101 hepatocellular carcinoma topline data is scheduled for the fourth quarter of 2026.

What Investors Expect From Tvardi Therapeutics, Inc. (NASDAQ:TVRD) on November 13, 2026

Tvardi Therapeutics is listed to report third quarter 2026 results before the market opens (BMO) on November 13, 2026. The consensus estimate per the screener snapshot is a loss of USD 0.57 per share. The second quarter loss was USD 0.69 per share and the six-month loss was USD 1.41 per share, so the estimate implies a narrower loss than the latest quarter. Market capitalization per the screener snapshot is USD 17.87 million, a nano-cap level with high Volatility and liquidity risk.

The Rationale: Last Reported Quarter and Management Outlook for Tvardi Therapeutics, Inc. (NASDAQ:TVRD)

In the second quarter of 2026, Research and Development expense was USD 4.0 million versus USD 5.8 million a year earlier, general and administrative expense was USD 2.6 million versus USD 3.1 million, and total operating expenses were USD 6.6 million versus USD 8.9 million. The six-month net loss was USD 13.3 million versus USD 5.4 million. Management reported healthy volunteer results for TTI-109, a next-generation STAT3 inhibitor, and plans an ulcerative colitis trial in 2027, subject to IND clearance and additional funding. The company cites more than 1.25 million diagnosed US patients and a USD 3 billion US market.

Valuation, Liquidity and Risks for Tvardi Therapeutics, Inc. (NASDAQ:TVRD)

Per the screener snapshot, the Market Value is USD 17.87 million. At June 30, 2026, total Assets were USD 8.4 million of Equity plus USD 9.1 million of liabilities, or USD 17.5 million, and stockholders' equity fell from USD 20.9 million at year-end to USD 8.4 million. Weighted-average shares were 9,381,344 in the second quarter. Cash declined by USD 15.0 million in six months, calculated. Risks include clinical trial outcomes, the need for added capital to advance TTI-109 and the small-cap profile typical of clinical-stage biotechs.

Where Things Stand

Where things stand: Tvardi Therapeutics, Inc. (NASDAQ:TVRD) reports third quarter 2026 results before the market opens on November 13, 2026, with a consensus EPS estimate of -0.57 and a market value of USD 17.87 million per the screener snapshot. Cash of USD 15.8 million funds operations through the hepatocellular carcinoma topline readout into the third quarter of 2027, according to management. Spending is falling, with second quarter operating expenses at USD 6.6 million, but equity has shrunk to USD 8.4 million. Investors will watch burn, financing plans, the TTI-109 investigational new drug path and any update on the fourth quarter TTI-101 data. This article is informational and is not Investment advice.